Cargando…
There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma
Glaucoma is a common eye disorder and an irreversible cause of blindness worldwide. There are several treatment options for this condition, with the traditional first-line treatment being ophthalmologic drops. Although administered topically, it is associated with inadvertent systemic absorption lea...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814563/ https://www.ncbi.nlm.nih.gov/pubmed/35154926 http://dx.doi.org/10.7759/cureus.20945 |
_version_ | 1784645091505209344 |
---|---|
author | Haga, Claire Waller, Thomas Ahuja, Abhimanyu S Farford, Bryan Dawson, Nancy Yin, Mingyuan |
author_facet | Haga, Claire Waller, Thomas Ahuja, Abhimanyu S Farford, Bryan Dawson, Nancy Yin, Mingyuan |
author_sort | Haga, Claire |
collection | PubMed |
description | Glaucoma is a common eye disorder and an irreversible cause of blindness worldwide. There are several treatment options for this condition, with the traditional first-line treatment being ophthalmologic drops. Although administered topically, it is associated with inadvertent systemic absorption leading to a potential for both local and systemic side effects. We discuss the case of a 71-year-old male who presented with a complaint of recurring episodes of distressing sensations including lightheadedness, dyspnea, chest pressure, and faintness. His past medical history included congestive heart failure, hypertension, hyperlipidemia, Barrett’s esophagus, and glaucoma. Upon a thorough review of the patient’s medications, it was discovered that he had recently been started on timolol ophthalmic drops. The patient then noted that his symptoms had begun after he started using the eye drops. After we recommended that the patient hold the use of the eye drops, these episodes stopped. When prescribing topical ophthalmologic drops, providers must educate patients on common systemic side effects of such drugs. |
format | Online Article Text |
id | pubmed-8814563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-88145632022-02-10 There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma Haga, Claire Waller, Thomas Ahuja, Abhimanyu S Farford, Bryan Dawson, Nancy Yin, Mingyuan Cureus Family/General Practice Glaucoma is a common eye disorder and an irreversible cause of blindness worldwide. There are several treatment options for this condition, with the traditional first-line treatment being ophthalmologic drops. Although administered topically, it is associated with inadvertent systemic absorption leading to a potential for both local and systemic side effects. We discuss the case of a 71-year-old male who presented with a complaint of recurring episodes of distressing sensations including lightheadedness, dyspnea, chest pressure, and faintness. His past medical history included congestive heart failure, hypertension, hyperlipidemia, Barrett’s esophagus, and glaucoma. Upon a thorough review of the patient’s medications, it was discovered that he had recently been started on timolol ophthalmic drops. The patient then noted that his symptoms had begun after he started using the eye drops. After we recommended that the patient hold the use of the eye drops, these episodes stopped. When prescribing topical ophthalmologic drops, providers must educate patients on common systemic side effects of such drugs. Cureus 2022-01-04 /pmc/articles/PMC8814563/ /pubmed/35154926 http://dx.doi.org/10.7759/cureus.20945 Text en Copyright © 2022, Haga et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Family/General Practice Haga, Claire Waller, Thomas Ahuja, Abhimanyu S Farford, Bryan Dawson, Nancy Yin, Mingyuan There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title | There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title_full | There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title_fullStr | There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title_full_unstemmed | There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title_short | There’s Danger in the Drops: Systemic Effects of Ophthalmic Drops Used to Treat Glaucoma |
title_sort | there’s danger in the drops: systemic effects of ophthalmic drops used to treat glaucoma |
topic | Family/General Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814563/ https://www.ncbi.nlm.nih.gov/pubmed/35154926 http://dx.doi.org/10.7759/cureus.20945 |
work_keys_str_mv | AT hagaclaire theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma AT wallerthomas theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma AT ahujaabhimanyus theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma AT farfordbryan theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma AT dawsonnancy theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma AT yinmingyuan theresdangerinthedropssystemiceffectsofophthalmicdropsusedtotreatglaucoma |